|1.||Strange, Poul: 1 article (03/2014)|
|2.||Newton, Roger S: 1 article (03/2014)|
|3.||Hanselman, Jeffrey C: 1 article (03/2014)|
|4.||Milad, Mark A: 1 article (03/2014)|
|5.||McBride, Scott J: 1 article (03/2014)|
|6.||Macdougall, Diane E: 1 article (03/2014)|
|7.||Gutierrez, Maria J: 1 article (03/2014)|
|8.||Rosenberg, Noah L: 1 article (03/2014)|
|9.||Margulies, Janice R: 1 article (03/2014)|
|10.||Munir, S M: 1 article (08/2012)|
|1.||Cardiovascular Diseases (Cardiovascular Disease)
12/01/2001 - "Intensive treatment with lipid-regulating agents, particularly statins, is often necessary to normalize diabetes-associated dyslipidemias. "
02/28/1990 - "[Dyslipoproteinemias: treatment with lipid regulating drugs]."
07/01/1998 - "Intensive treatment with lipid-regulating agents, particularly HMG-CoA reductase inhibitors, is often necessary to normalize diabetes-associated dyslipidemias. "
09/01/2004 - "Simvastatin and fenofibrate are both commonly used lipid-regulating agents with distinct mechanisms of action, and their coadministration may be an attractive treatment for some patients with dyslipidemia. "
01/01/2003 - "Diet and treatment with 3-hydroxi-3-metilglutaril coenzyme A (HMG-CoA) reductase inhibitors helps to reduce low density lipoprotein cholesterol (LDL-Ch) blood concentration up to recommended level of 3.0 mmol/l in most patients but in some patients particularly with familial dyslipidemias cholesterol concentration remains increased even after treatment with maximal doses of lipid-regulating agents or their combinations. "
|3.||Kidney Diseases (Kidney Disease)
08/01/2012 - "Patients were excluded if alcoholic, diabetic, hypertensive, or with non-alcoholic fatty liver disease, autoimmune, metabolic, cardiovascular, cerebrovascular or kidney diseases and recent use of lipid-regulating drugs. "
01/01/2010 - "The clinical evidence and recommendations for the use of lipid-regulating drugs in patients with chronic kidney disease, nephrotic syndrome, in patients undergoing hemo- and peritoneal dialysis and in transplanted patients was also reviewed. "
|4.||Nephrotic Syndrome (Syndrome, Nephrotic)
|1.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|5.||Coenzyme A (CoA)
|7.||Non-alcoholic Fatty Liver Disease
|1.||Transplantation (Transplant Recipients)